Progression-free survival and OS in patients receiving CHOP or CHOP-like plus rituximab by the HLA. (A,B) Presence of HLA-B*18 vs other polymorphisms. (C,D) Presence of HLA-B44 supertype vs other polymorphisms. (E,F) Presence of HLA-B*18 vs other HLA-B44 supertype polymorphisms vs other HLA polymorphisms.